CHANDAN HEALTHCARE LIMITED (CHANDAN): Financials & Fundamentals History

Share Price

₹235.00

P/E

23.2x

ROCE

23.0%

Market Cap

₹575 cr

Revenue (TTM)

₹289 cr

P/S

2.0x

P/B

3.4x

ROE

14.5%

Operating Margin

24.2%

Debt / Equity

0.3x

Promoter Holding

49.6%

12M Momentum

-27.9%

52-week range

₹185.40₹358.00

29% of the way from its 52-week low to its high

Price risk

1Y volatility

50.4%

Beta vs sector

1-year daily

0.80

Balance sheet & cash

Interest cover

operating profit ÷ interest

5.0x

Cash from profit, 3Y

operating cash flow ÷ net profit

0.20x

low

Share count, 1Y

unchanged

Was the rally earned?

-28%share price, 1 yearLower P/E held it back

Earnings helped, the multiple did not.

Per-share earnings added 9 points, but investors now pay less per rupee of profit (P/E 35.9x to 23.2x), which took 37 points back.
The share count fell 8%.

Net profit growth+3 ptsNet profit rose about 3%, which lifts the price.

P/E change-37 ptsThe P/E fell from 35.9x to 23.2x, which lowers the price.

Share count change+7 ptsShare count fell 8%, which lifts the price.

What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Not shown for 3 years and 5 years: earnings were negative at one end, or there is not enough history.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with DR. LAL PATHLABS

What is the price implying?

~24%annual earnings growth implied by the price

At a P/E of 41.2x, the price would imply about 23.9%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.

Fewer than six years of annual earnings are available, which is too little to measure delivered growth.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

What prices imply across Health Services The market-wide Expectations lists

What changed?

Sep '26Fell 45% from the Nov 2025 peak to the Sep 2026 low.
Sep '26Moved into the 2nd quartile of Health Services on operating margin (from the bottom quartile).
Jul '26Volume reached 5.5x its 50-day median on 2026-07-02; price -8.1% that day.
Jun '26Slipped to the bottom quartile of Health Services on operating margin (from the 3rd quartile).
Jun '26Volume reached 14.5x its 50-day median on 2026-06-19; price +2.1% that day.
Mar '26Volume reached 10.4x its 50-day median on 2026-03-09; price -4.0% that day.
Feb '26Debt / equity halved over 12 months to 0.39x.
Feb '26Share count is up 20.0% over 12 months.

Show 4 earlier events

Dec '25FII + DII holding fell 4.0 pts over 1 quarter to 6.1%.
Oct '25Volume reached 28.7x its 50-day median on 2025-10-14; price +2.9% that day.
Sep '25Volume reached 42.1x its 50-day median on 2025-09-22; price +5.0% that day.
May '25Volume reached 5.7x its 50-day median on 2025-05-27; price +7.0% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Are profits backed by cash?

3 of 5 checks are within range, 2 beyond a threshold.
Tap a check to see how it is measured.

Other income reliance7%Within range

Other income as a share of pre-tax profit (trailing twelve months): 7.1%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate29%Within range

Median quarterly effective tax rate over about 2.5 years: 29.1%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion0.20xBeyond threshold

Operating cash flow divided by net profit over the last three fiscal years: 0.20x (cash from operations ₹14 cr, net profit ₹69 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow0 of 5 yrsBeyond threshold

Fiscal years with positive free cash flow in the last 5: 0. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history—Not enough data

Not enough reported data to compute this.

Capital work in progress12% of fixed assetsWithin range

Capital work-in-progress is 12% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days—Not enough data

Not enough reported data to compute this.

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

Since Mar 2025, FIIs trimmed 3.9 pts; DIIs trimmed 1.2 pts.
The number of shareholders rose from 897 to 1,591 (+77%) between Mar 2025 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupMar '25Jun '26Change

Promoters49.4%49.6%+0.2 pts

FIIs3.9%0.0%-3.9 pts

DIIs6.3%5.1%-1.2 pts

Public and others40.4%45.3%+4.9 pts

Number of shareholders

1,591shareholders+77% since Mar '25

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

How rough has the ride been?

Maximum drawdown-45.0%not yet recovered

1-year volatility50.4%annualised

Beta vs sector index0.803-year daily, correlation 0.25

Volume spikes5last 90 sessions, 5x the 50-day median

Monthly share price

Last 90 trading days

Drawdown from peak

Largest drawdowns

-45.0% (2025-11 peak to 2026-09 low, not yet recovered)

-19.3% (2025-04 peak to 2025-05 low, recovered 2025-06)

-15.9% (2025-07 peak to 2025-09 low, recovered 2025-10)

Most recent volume spikes

2026-07-02: 5.5x the 50-day median, price -8.1% that day

2026-06-30: 5.8x the 50-day median, price +6.7% that day

2026-06-29: 5.7x the 50-day median, price +6.8% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Where does it rank among Health Services peers?

Each cell is the company's percentile rank among its Health Services peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

ROCE

Op. margin

Revenue growth

EPS growth

Debt/equity ↓

Cash cycle ↓

P/E ↓

12M momentum

Nov '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Oct '26

Lower rank Higher rank

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Services sector page Watch it move against Health Services in the Observatory

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

Company	Sector	Similarity	Closest on
JARO INSTITUTE OF TECHNOLOGY M (JARO)	Consumer Services	57%	debt/equity, revenue
MATRIMONY.COM (MATRIMONY)	Technology Services	57%	P/E, revenue
OSEL DEVICES (OSELDEVICE)	Electronic Technology	55%	ROCE, revenue
FLYSBS AVIATION (FLYSBS)	Transportation	54%	revenue, volatility
ANLON HEALTHCARE (AHCL)	Health Technology	51%	revenue, ROCE
SURAKSHA DIAGNOSTIC (SURAKSHA)	Health Services	38%	promoter holding, revenue
KRSNAA DIAGNOSTICS (KRSNAA)	Health Services	30%	operating margin, debt/equity
UNIHEALTH HOSPITALS (UNIHEALTH)	Health Services	21%	ROCE, revenue

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What happened next to similar setups

+1.0%typical 12-month return vs the marketNot meaningfully different from the base rate

We found 50 past situations where a non-financial company looked like CHANDAN HEALTHCARE LIMITED today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
Over the following 12 months the middle half of them returned −23% to +35% vs the market, against −4% for all non-financial companies in the same months.
The gap against the base rate (+4.7%, 80% range −2.5% to +9.6%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 2 beyond the range shown, drawn at the edge

Similar setups' median

+1.0%

All companies' median

−3.7%

Beat the market

52% vs 46%

50 past situations · 50 companies · 32 months · 2020–2025

The closest matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
CARYSIL Consumer Durables	May 2023	23x	27%	−5%	−23%	−1%
AWHCL Transportation	May 2022	19x	18%	−1%	−33%	−23%
ROTO Producer Manufacturing	Feb 2024	36x	26%	+34%	−15%	+7%
JASH Producer Manufacturing	Aug 2024	38x	25%	+41%	−19%	+35%
VADILALIND Consumer Non-Durables	Aug 2020	12x	17%	+3%	−21%	−3%

Show the other 3 matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
MOLDTKPAC Producer Manufacturing	Jun 2020	15x	19%	−26%	−36%	+46%
SANGHVIMOV Industrial Services	Oct 2022	33x	—	+2%	−16%	+197%
SIGACHI Health Technology	Jun 2025	24x	16%	−19%	−28%	−51%

How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: 12-month momentum, P/E and drawdown from 12-month high. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to CHANDAN HEALTHCARE LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-10-30. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

Feature	Weight	Non-financial	Financial
P/E	1	yes	yes
P/S	1	yes	—
P/B	1	—	yes
ROCE	1	yes	—
operating margin	1	yes	—
ROE	1	—	yes
debt/equity	0.75	yes	—
interest cover	0.5	yes	—
revenue growth	0.75	yes	yes
12-month momentum	1	yes	yes
drawdown from 12-month high	0.75	yes	yes
size	0.75	yes	yes
volatility	0.5	yes	yes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
Pools: non-financial: 97,430 company-months from 2000 companies; financial: 5,632 company-months from 106 companies. 2240 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Monthly history (21 months)

Month	P/E	Revenue (TTM)	ROE	ROCE	Debt / Equity
2026-10	23.2x	₹289 cr	14.5%	23.0%	0.3x
2026-09	23.0x	₹289 cr	14.7%	23.0%	0.3x
2026-08	23.7x	₹276 cr	13.7%	23.0%	0.3x
2026-07	25.4x	₹276 cr	13.7%	23.0%	0.3x
2026-06	29.6x	₹276 cr	13.7%	23.0%	0.3x
2026-05	24.6x	₹263 cr	20.1%	29.0%	0.4x
2026-04	25.5x	₹263 cr	20.1%	29.0%	0.4x
2026-03	22.2x	₹263 cr	20.1%	29.0%	0.4x
2026-02	25.7x	₹253 cr	19.8%	29.0%	0.4x
2026-01	26.3x	₹253 cr	19.8%	29.0%	0.4x
2025-12	32.1x	₹253 cr	19.8%	29.0%	0.4x
2025-11	36.7x	₹230 cr	19.7%	29.0%	0.4x
2025-10	35.9x	₹230 cr	19.7%	29.0%	0.4x
2025-09	25.5x	₹230 cr	19.7%	29.0%	0.4x
2025-08	24.2x	₹230 cr	19.7%	29.0%	0.4x
2025-07	28.3x	₹230 cr	19.7%	29.0%	0.4x
2025-06	20.5x	₹230 cr	19.7%	29.0%	0.4x
2025-05	22.7x	₹177 cr	39.0%	37.0%	0.9x
2025-04	22.6x	₹177 cr	39.0%	37.0%	0.9x
2025-03	22.2x	₹177 cr	39.0%	37.0%	0.9x
2025-02	19.4x	₹177 cr	39.0%	37.0%	0.9x

Methodology and data notes